The Fox Chase Chemical Diversity Center Will Be Presenting Riluzole Prodrugs to Treat ALS and Melanoma, Funded by a Phase II SBIR Grant, at the NCI SBIR Investor Forum on Nov. 13 in Santa Clara, CA
Doylestown, PA. September 8, 2014– FCCDC will be presenting Riluzole Prodrugs to treat ALS and melanoma, funded by a Phase II SBIR grant, at the NCI SBIR Investor Forum on Nov. 13 in Santa Clara, CA (http://sbir.cancer.gov/investorforum/presenters.asp).